ENTRY       D12262            Mixture   Drug
NAME        Tixagevimab and cilgavimab;
            Tixagevimab (genetical recombination) and cilgavimab (genetical recombination);
            Evusheld (TN)
PRODUCT
  OTHER     EVUSHELD (AstraZeneca Pharmaceuticals LP)
COMPONENT   Tixagevimab [DR:D11993], Cilgavimab [DR:D11994]
CLASS       Antiviral
             DG03174  Anti-SARS-CoV-2 agent
REMARK      Therapeutic category: 6250
            ATC code: J06BD03
            Product: D12262<JP/US>
EFFICACY    Antiviral
  DISEASE   Coronavirus disease 2019 [DS:H02398]
  TYPE      Monoclonal antibody, combination
COMMENT     For the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19)
TARGET      SARS-CoV-2 spike glycoprotein [KO:K24152]
  PATHWAY   ko03230(K24152)  Viral genome structure
            ko05171(K24152)  Coronavirus disease - COVID-19
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J06 IMMUNE SERA AND IMMUNOGLOBULINS
               J06B IMMUNOGLOBULINS
                J06BD Antiviral monoclonal antibodies
                 J06BD03 Tixagevimab and cilgavimab
                  D12262  Tixagevimab and cilgavimab &lt;JP/US&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D12262  Tixagevimab and cilgavimab
            Drug groups [BR:br08330]
             Antiviral
              DG03174  Anti-SARS-CoV-2 agent
               D12262  Tixagevimab and cilgavimab
            Drug classes [BR:br08332]
             Antiviral
              DG03174  Anti-SARS-CoV-2 agent
               D12262  Tixagevimab and cilgavimab
            Antimicrobials [BR:br08307]
             Antivirals
              Entry, fusion or uncoating inhibitor
               Coronavirus spike protein
                D12262  Tixagevimab and cilgavimab &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12262
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D12262
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12262
///
